Skip to Main Content
Try STAT+ TODAY
Trending:
The Obesity Revolution
Health
STAT+
Biotech
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Business
STAT+

Vertex shuts down study of long-acting Kalydeco but insists development still on track

  • Adam Feuerstein

By Adam Feuerstein Sept. 11, 2017

Reprints
Kalydeco
Yoon S. Byun/The Boston Globe

Updated with Vertex comment.

Vertex Pharmaceuticals (VRTX) terminated a small clinical trial involving an important, long-acting version of its cystic fibrosis drug Kalydeco that was acquired from Concert Pharmaceuticals (CNCE) earlier this summer.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Adam Feuerstein

Adam Feuerstein

Senior Writer, Biotech

Adam Feuerstein is STAT’s national biotech columnist, reporting on the intersection of biotech and Wall Street. He's also a co-host of "The Readout LOUD" podcast.

Tags

The lab leak conversation shows it’s time to rethink…
The lab leak conversation shows it’s time to rethink our biosecurity infrastructure, not just policies
Watch: P-value, an important measurement in clinical trials, explained
Watch: P-value, an important measurement in clinical trials, explained
Physicians aren’t ‘burning out.’ They’re suffering from moral injury
Physicians aren’t ‘burning out.’ They’re suffering from moral injury
8 burning questions Bernie Sanders and other senators should…
8 burning questions Bernie Sanders and other senators should ask Moderna’s Stéphane Bancel
Senator calls for probe of conflict of interest on…
Senator calls for probe of conflict of interest on federal panel overseeing dietary guidelines
Top FDA official: Agency needs to start using accelerated…
Top FDA official: Agency needs to start using accelerated approval for gene therapies

Recommended Stories